Evidence map›Paper›PMID 42446166›Full record

ArticleHematological oncology2026

Clinical Significance of FLT3-ITD Variation Allele Frequency in Acute Myeloid Leukemia: A Multicenter Study.

Laibing Guo, Jingyan Song, Haoyu Zang, Yang Cao, Yan Lin, Zhuojun Zheng, Suning Chen, Lijun Wen, Yuqing Miao, Weiying Gu

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Laibing GuoDepartment of Hematology, The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, China.ORCID https://orcid.org/0009-0000-4425-924X
Jingyan SongDepartment of Hematology, The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, China.
Haoyu ZangDepartment of Hematology, The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, China.
Yang CaoDepartment of Hematology, The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, China.
Yan LinDepartment of Hematology, The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, China.
Zhuojun ZhengDepartment of Hematology, The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, China.
Suning ChenDepartment of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Lijun WenDepartment of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0000-0002-1694-2700
Yuqing MiaoDepartment of Hematology, Yancheng First People's Hospital, Yancheng, China.
Weiying GuDepartment of Hematology, The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, China.ORCID https://orcid.org/0000-0003-4913-1610

Funding

Changzhou Medical Center, Nanjing Medical University CMCB202311Key project of Jiangsu Province Health Committee ZD2021043
6 · The paper itself

Abstract

The specific prognostic impact of FLT3-ITD variant allele frequency (VAF) in acute myeloid leukemia (AML) remains unclear. In this multi-center study of 190 AML patients harboring FLT3-ITD mutations, a VAF cut-off of 40% was applied. Patients with high VAF (≥ 40%) exhibited significantly higher white blood cell counts, lactate dehydrogenase levels, and bone marrow blast percentages, alongside markedly shorter median overall survival (OS). Although high VAF was independently associated with inferior outcomes in the overall multivariate Cox regression analysis, its effect was profoundly amplified in the presence of co-mutations in NPM1 or DNMT3A. This suggests that high VAF may function not as an absolute, independent determinant, but primarily as a potent "risk amplifier." Notably, allogeneic hematopoietic stem cell transplantation (allo-HSCT) effectively mitigated this survival disadvantage. Furthermore, we characterized a non-linear relationship between VAF and mortality risk, with a sharp increase observed once the VAF burden exceeded 34%. In conclusion, a quantitative VAF ≥ 40% should be considered a context-dependent prognostic marker for risk stratification. Allo-HSCT represents a critical intervention capable of overcoming the exceedingly poor prognosis associated with high VAF.

Indexed as

fms-Like Tyrosine Kinase 3Gene FrequencyLeukemia, Myeloid, AcuteMutationAdultAgedDNA Methyltransferase 3AFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedNucleophosminPrognosisYoung AdultDNA Methyltransferase 3ADNMT3A protein, humanFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNucleophosminacute myeloid leukemiaFLT3‐ITDHSCTprognosisvariant allele frequency

Identifiers

PMID42446166
PMCPMC13367014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.